北京大学肿瘤研究中心是2002年由原来的“北京大学癌研究中心”更名为“北京大学肿瘤研究中心”。现任研究中心主任季加孚教授，中心学术委员会主任尹玉新教授。北京大学肿瘤研究中心旨在整合北京大学优势力量与优势资源，临床与基础紧密结合，建设国内领先、国际认可的肿瘤医学研究转化平台。

　　研究领域及方向：以临床需求为主，主要包括通过癌前病变的早期发现与分子分型，寻找癌变过程的驱动因素及其干预手段，为降低肿瘤发病率提供手段；发现恶性肿瘤早期筛查或诊断标志物，优化早诊技术，提高早癌检出率；发现恶性肿瘤预后判断或疗效预测标志物，实现肿瘤的分子分型，为制定患者的个体化诊疗方案提供依据；建立有效的肿瘤治疗和疗效早期判断方法，优化治疗方案，提高患者的生存率和生活质量。

　　中心有一支专门从事肿瘤基础研究及应用基础研究的科研队伍，既有国际上具学术影响力的多名学科带头人，又具有较强开拓创新能力的年轻学术骨干，有较强的整体研究实力和国际学术竞争能力。目前有中科院院士1人，中国工程院院士1人（2016年引进），美国医学科学院院士1人，长江学者特聘教授3人，国家杰出青年基金获得者5人，青年千人1人。建有胃癌和食管癌两大高发现场和符合国际标准的生物样本库。

　　以我国常见恶性肿瘤为主攻方向，充分利用已建立的肿瘤高发现场及丰富的临床病例资源，发挥流行病学、遗传学、病因学、分子生物学、病理学及临床医学多学科协作优势，开展了肿瘤病因与发病机制、高危人群干预及早诊早治、临床诊疗靶点发现及药物研发研究，在胃癌、食管癌、肝癌、肺癌、乳腺癌、恶性黑色素瘤等肿瘤发病机制及转化研究方面取得了重要进展。例如，首次采用随机对照研究证明根除幽门螺杆菌感染可以有效降低人群胃癌发病率，研究成果成为世界卫生组织（WHO）制定胃癌预防策略的依据；耐药性恶性黑色素瘤的新型个体化治疗方案在国际上引起广泛关注，并纳入国际指南；胃癌综合防治体系建立取得重要成果，得到国际同行的高度认可，季加孚教授当选为国际胃癌学会主席，获得2017年第十二届世界胃癌大会主办权并成功举办，使中国首次成为世界胃癌大会的主办国。同时，发现了新型组蛋白修饰酶HAT4和JMJD2B等；制备了能够靶向钙离子通道蛋白a2d1的单克隆抗体1B50-1，有清除肿瘤起始细胞的作用；研发了抑制肿瘤血管生成的肽类新药FpAT，获得了国家食品药品监督管理总局CFDA颁发的1.1类抗肿瘤新药的临床试验批件。研究结果发表在Lancet Oncol、Cancer Cell、J Clin Oncol、Gut、JNCI、Nat Commun、Genome Biol等国际知名刊物上。

　　

　　机构负责人：季加孚

　　联系人：贾淑芹

　　邮箱：kjc126@163.con

　　电话：88196926

　　地址：北京市海淀区阜成路52号

　　

　　

　　Peking University Cancer Research Center

 

　　Peking University Cancer ResearchCenter was established in 2002, which was renamed from Peking University Malignant Tumor Research Center. The director of the Center is Professor Ji Jia-fu, and the chairman of the Academic Committee is Professor Yin Yu-xin. The mission of the Center is to integrate the strengths and resources of Peking University, and bridge the gap between basic research and clinical practice, so as to set up a translational research platform which is the best in China and internationally recognized.

　　Based on the clinical needs, the Center aims to reduce cancer incidenceby seeking the driving factorsin cancer progression and corresponding interventions through early detection and molecular classification of precancerous lesions; investigating biomarkers for cancer screening and early diagnosis to improve the rate of cancer early detection; identifying cancer prognostic and predictive biomarkers to achieve cancer molecular classification, providing evidence for developing personalized diagnosis and treatment; developing effective methods for cancer treatment and evaluation of early treatment efficacy, optimizing the treatment protocol to improve patients’ survival rate and quality of life.

　　The Center has a research team engaged in cancer related basic and translational research, which consists of world-renowned academic pacemakers and promising and innovative young scientists, making it strong in research capacity and international academic competitiveness. Currently, the research team has one member of the Chinese Academy of Sciences, one member of the Chinese Academy of Engineering (recruited in 2016), one member of the American Academy of Medical Sciences, three chair professors of “Chang Jiang Scholars Program”, five awardees of the National Science Fund for Distinguished Young Scholars, and one member of the Young Overseas High-Level Talents Introduction Plan. Two population-based research fields in the high risk areas of gastric cancer and esophageal cancerhave been set up and a bio-bank in line with international standards has been established.

　　Focusing on common cancers in China, the Center takes full advantage of the two established population-based cohorts, the large number of clinical cancer cases, and its strength in multidisciplinary cooperation among epidemiology, genetics, etiology, molecular biology, pathology and clinical medicine to carry out research in cancer etiology and pathogenesis; intervention, cancer early diagnosis and treatment for high-risk population; identification of targets for cancer diagnosis and treatment and corresponding drug research and development, and has made significant progress in carcinogenesis and translational research in gastric cancer, esophageal cancer, liver cancer, lung cancer, breast cancer, malignant melanoma, etc. For example, we have, for the first time, demonstrated that eradication of Helicobacter pylori can reduce the incidence of gastric cancer through randomized controlled intervention trial, and the findings have been adopted by the World Health Organization (WHO) as evidence for development of strategies for gastric cancer prevention. We developed the new individualized treatment protocol for drug-resistant malignant melanoma, which attracted great international attention and was integrated into the international guidelines. The comprehensive gastric cancer prevention and control system we established was highly recognized by the international community, and Professor Ji Jia-fu was elected as chairman of the International Gastric Cancer Association, and China, for the first time, won the bid for hosting the 12^th International Gastric Cancer Conference in 2017. The major findings also included the discovery of new histone-modifying enzymes of HAT4 and JMJD2B; production of monoclonal antibody 1B50-1 which can target calcium channel protein a2d1 and eliminate tumor initiating cells; development of a new peptide drug FpAT that inhibits tumor angiogenesis, which has obtained clinical trial approval of Class 1.1 new antitumor drug issued by the China Food and Drug Administration. The findings were published in the internationally renowned publications such as Lancet Oncol, Cancer Cell, J Clin Oncol, Gut, JNCI, Nat Commun, and Genome Biol.

　　

　　Director: Ji Jia-fu

　　Contact: Jia Shu-qin

　　E-mail: kjc126@163.con

　　Phone: 8610-88196926

　　Address: 52 Fucheng Road, Haidian District, Beijing